Olverembatinib plus immunotherapy versus olverembatinib plus allogeneic hematopoietic cell transplantation in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
Philadelphia chromosome–positive (Ph⁺) acute lymphoblastic leukemia (ALL) accounts for approximately 20–30% of adult B-cell ALL cases [ 1 ]. Historically, Ph⁺ ALL has been associated with poor outcomes due to intrinsic chemoresistance. The integration of BCR::ABL1 tyrosine kinase inhibitors (TKIs) into frontline induction regimens has dramatically improved complete remission (CR) rates to >95%. Allogeneic hematopoietic cell transplantation (allo-HSCT) remains the standard consolidation strategy for patients in first CR [ 2 ].
Authors
- Jie Jin (ORCID: https://orcid.org/0000-0002-8166-9915)
- Wanzhuo Xie (ORCID: https://orcid.org/0000-0002-0966-5581)
- Yinjun Lou (ORCID: https://orcid.org/0000-0003-4495-2460)
- Wenjuan Yu (ORCID: https://orcid.org/0000-0002-5439-141X)
- Hongyan Tong (ORCID: https://orcid.org/0000-0001-5603-4160)
- Liangshun You (ORCID: https://orcid.org/0000-0003-4575-3287)
- Min Yang
- Yanling Ren (ORCID: https://orcid.org/0000-0003-0874-7806)
- Xingnong Ye (ORCID: https://orcid.org/0000-0002-2657-6716)
- Gaixiang Xu (ORCID: https://orcid.org/0000-0002-4932-5813)
- Huafeng Wang (ORCID: https://orcid.org/0000-0002-8360-6395)
- Chenying Li (ORCID: https://orcid.org/0000-0002-4986-6345)
- Jiejing Qian
- Jian Huang
- Xinping Zhou
- Liping Mao
- De Zhou
- Haitao Meng
Institutions
- Zhejiang Cancer Hospital (CN)
- Zhejiang Technical Institute of Economics (CN)
- First Affiliated Hospital Zhejiang University (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Blood Cancer Journal
- Published
- 2026-07-27
- DOI
- https://doi.org/10.1038/s41408-026-01591-y
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Zhejiang University